Researchers from The George Washington University and Northwestern University filed for protection of a bioresorbable, transparent, microelectrode array (MEA) technology that they believe offers unique advantages.
Fire1 Ltd. secured $120 million in financing to conduct a pivotal trial for its heart failure management system, Norm. The technology measures fluid in the inferior vena cava (IVC) and is expected to help the millions of people living with heart failure manage their condition and get their normal life back.
Fauna Bio Inc. has nominated Faun-1083 as its first development candidate, for the treatment of heart failure with preserved ejection fraction (HFpEF). Faun-1083 is a novel small-molecule therapeutic that has demonstrated promising in vivo efficacy in multiple preclinical animal models.
Administrators at the U.S. Medicare program have proposed to cover the Cardiomems remote monitoring device for heart failure, but cardiologists are averse to several of the conditions spelled out in the draft coverage memo, including what they see as a somewhat futile demand for a comparator arm in the proposed coverage study.
Secretome Therapeutics Inc. has closed a $20.4 million round of financing to support its development of therapies derived from neonatal cardiac progenitor cells.
At the American Heart Association’s Scientific Sessions, E-Therapeutics plc presented preclinical data for ETX-258, a Galomic siRNA being developed for the treatment of heart failure.
Researchers from Liaoning Jinqiu Hospital and affiliated organizations explored potential new genetic targets in heart failure and breast cancer through combining genetic inference and single-cell expression analysis. Genome-wide association study (GWAS) identified multiple genetic variants that were causally related in heart failure and breast cancer.
Researchers from Liaoning Jinqiu Hospital and affiliated organizations explored potential new genetic targets in heart failure and breast cancer through combining genetic inference and single-cell expression analysis. Genome-wide association study (GWAS) identified multiple genetic variants that were causally related in heart failure and breast cancer.
Researchers from UCLA’s Department of Cardiac Surgery filed for protection of a smart multistage peripherally inserted cannula with active fixation for temporary cardiopulmonary support which simultaneously drains both sides of the heart.
Researchers from Corteria Pharmaceuticals SAS and Université Paris-Saclay recently presented the preclinical results on a long-acting corticotropin-releasing factor CRF2 receptor agonist, COR-1389.
